Align Technology (BSP:A1LG34) ROCE % : 17.93% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Align Technology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Align Technology's annualized ROCE % for the quarter that ended in Dec. 2023 was 17.93%.

Align Technology ROCE % Historical Data

The historical data trend for Align Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Align Technology ROCE % Chart

Align Technology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

36.53

16.39

27.10

15.66

15.78

Align Technology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															12.22	13.44	16.73	16.30	17.93

Align Technology ROCE % Calculation

Align Technology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	3217.473	/	( ( (31199.361 - 10102.048)	+	(29809.781 - 10125.981) )	/ 2 )
	=	3217.473	/	( (21097.313	+	19683.8)	/ 2 )
	=	3217.473	/	20390.5565
	=	15.78 %

Align Technology's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	3623.128	/	( ( (31205.428 - 10484.791)	+	(29809.781 - 10125.981) )	/ 2 )
	=	3623.128	/	( ( 20720.637	+	19683.8 )	/ 2 )
	=	3623.128	/	20202.2185
	=	17.93 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Align Technology (BSP:A1LG34) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Align Technology ROCE % Related Terms

Thank you for viewing the detailed overview of Align Technology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Align Technology (BSP:A1LG34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Align Technology Inc (BSP:A1LG34) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ALGN:USA ALGN:Mexico AFW:Germany AFW:Germany

Address

410 North Scottsdale Road, Suite 1300, Tempe, AZ, USA, 85281

Website

https://www.aligntech.com

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the FDA in 1998, and it has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans and iTero scans make up over half of these scans.

Align Technology (BSP:A1LG34) Headlines

No Headlines